Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC by Mishra, Rajashree et al.
Genetic Discrimination Between
LADA and Childhood-Onset
Type 1 Diabetes Within the MHC
Diabetes Care 2020;43:418–425 | https://doi.org/10.2337/dc19-0986
OBJECTIVE
TheMHC region harbors the strongest loci for latent autoimmunediabetes in adults
(LADA); however, the strength of association is likely attenuated compared with
that for childhood-onset type 1diabetes. In this study,we recapitulate independent
effects in the MHC class I region in a population with type 1 diabetes and then
determine whether such conditioning in LADA yields potential genetic discrim-
inators between the two subtypes within this region.
RESEARCH DESIGN AND METHODS
Chromosome 6 was imputed using SNP2HLA, with conditional analysis performed
in type 1 diabetes case subjects (n 5 1,985) and control subjects (n 5 2,219). The
same approach was applied to a LADA cohort (n 5 1,428) using population-based
control subjects (n52,850) and ina separate replication cohort (656 type1diabetes
case, 823 LADA case, and 3,218 control subjects).
RESULTS
The strongest associations in the MHC class II region (rs3957146, b [SE] 5 1.44
[0.05]), as well as the independent effect of MHC class I genes, on type 1 diabetes
risk, particularly HLA-B*39 (b [SE]5 1.36 [0.17]), were confirmed. The conditional
analysis in LADA versus control subjects showed significant association in the MHC
class II region (rs3957146, b [SE] 5 1.14 [0.06]); however, we did not observe
significant independent effects of MHC class I alleles in LADA.
CONCLUSIONS
In LADA, the independenteffectsofMHCclass I observed in type1diabeteswerenot
observedafter conditioningon the leadingMHCclass II associations, suggesting that
the MHC class I association may be a genetic discriminator between LADA and
childhood-onset type 1 diabetes.
Latent autoimmune diabetes in adults (LADA) is typically defined as initial insulin
independency for at least 6 months after diagnosis and the presence of diabetes-
associated autoantibodies (1). Despite such features, autoantibody screening is not
carriedout in routine clinical practice, resulting in frequentmisdiagnosis. For instance,
in a cohort of apparent type 2 diabetes cases, as many as 8–10% can actually
represent misdiagnosed autoimmune diabetes cases (2,3). Hence, there is a need to
identify biomarkers to aid in accurately diagnosing LADA as well as other diabetes
subtypes (4).
A comprehensive analysis of the genetic etiology of LADA has, until recently, not
been performed (5). Previous genetic studies have suggested that the condition
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14CNRS 8199, Université Lille Nord de France,
Pasteur Institute, Lille, France
15Department of Genomics of Common Disease,
Imperial College London, London, U.K.
16National Disease Research Interchange, Phil-
adelphia, PA
17Hospitalde laSantaCreu i SantPau,CIBERDEM,
Barcelona, Spain
18German Diabetes Center, Düsseldorf, German
19Diabetes Research Centre, University of Leices-
ter, Leicester, U.K.
Rajashree Mishra,1,2 Mikael Åkerlund,3
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comprised both type 1 diabetes and type
2 diabetes components either because it
is an intermediate form of diabetes or
because it is a mixture of type 2 diabetes
in a cohort of predominantly type 1 di-
abetes owing to a high false positive de-
tection rate with use of autoantibodies
when screening. There is some debate as
towhether LADA is in facta distinct clinical
entity or simply a category imposed on con-
tinuous features such as age of onset and
time to insulin. However, since LADA is cur-
rently defined as a slowly progressive form
of type1diabetes (6), it is crucial todefine
genetic differences between childhood-
onset type 1 diabetes and LADA if we are
to clarify the clinical utility of identifying
adult-onset autoimmune diabetes.
Previous genetic studies in LADA have
shown a strong association signal in the
MHC, although with diminished effect
sizes compared with observations in
childhood-onset type 1 diabetes (5,7). The
MHC region is located on chromosome
6 and harbors.400 genes,with twomain
classes, MHC class I and MHC class II, which
together harbor classic HLA genes (HLA-A,
HLA-B, HLA-C, and HLA-DRB, HLA-DQA,
HLA-DQB, HLA-DPA, and HLA-DPB, respec-
tively). The HLA encodes cell surface pro-
teins for antigen presentation and
accounts for ;50% of the genetic herita-
bility of type 1 diabetes, with susceptibility
principally harbored within the MHC class
II genes HLA-DQB1 and HLA-DRB1. How-
ever, in addition to class II genes,MHC Class
I genes in susceptibility to type 1 diabetes
have also been suggested in previous stud-
ies (8–10); in particular, variation within the
MHC class I genes HLA-A and HLA-B has
been shown through conditional analysis
to further increase type 1 diabetes risk
(11). MHC class I markers have also been
shown to be associated with younger age
at diagnosis in type 1 diabetes, and given
the adult-onset phenotype of LADA, we
hypothesized that this genetic variation
will be less enriched in LADA.
First, we aimed to recapitulate the
independent effects of MHC class I var-
iants using the SNP2HLA imputation tool
followed by stepwise forward logistic re-
gression in the same type 1 diabetes co-
hort that participated in a previous study
(11). In addition, we set out to identify
distinguishing features within the MHC be-
tween childhood-onset type 1 diabetes
and adult-onset LADA by performing the
same conditional analysis followed by a
replication attempt in a second case/control
set. Finally, we compared b regression
coefficients for each disease to deter-
mine whether effect sizes differ among
LADA case and control subjects versus
type1diabetes caseandcontrol subjects.
RESEARCH DESIGN AND METHODS
Study Populations
LADA Case Subjects
A total of 1,492 LADA cases were derived
from multiple cohorts across the U.K., Ger-
many, and the U.S. Details on the partic-
ipants canbe found in Supplementary Table
1. All participantswerediagnosedwith LADA
if they fulfilled the following criteria: age at
diagnosis 30–70years, testingpositive for at
least one diabetes-associated autoantibody
(most case subjects were positive for GAD
autoantibodies), and not on insulin treat-
ment for at least 6 months after diagnosis.
Control Subjects
The LADA population-based control sub-
jectscomprisedof twocohorts (n52,979).
Thefirst cohort consistedof 1,296 children
and adolescents of European ancestry
who did not have diabetes, aged 5–20
years, and who were enrolled in the Bone
Mineral Density in Childhood Study
(BMDCS) (12). The second control co-
hort consisted of 1,683 adults of Euro-
pean ancestry from a non-Hodgkin
lymphoma genome-wide association
study (GWAS), available in dbGaP
(www.ncbi.nlm.nih.gov/projects/gap/
cgi-bin/study.cgi?study_id5phs000818.v2
.p1) (13). Details on the control cohorts
can be found in Supplementary Table 1.
Recapitulating a Previous Study
We also leveraged 3,000 healthy adult
BritishBirthCohortcontrol subjects,2,000
individuals with childhood-onset type 1
diabetes, and1,999 individualswith type2
diabetes from the Wellcome Trust Case
Control Consortium (WTCCC) (14) to re-
capitulateobservations inapreviousstudy
(11). Individual data from the WTCCC are
available through the consortium’s Data
AccessCommittee (http://www.wtccc.org
.uk). More details on cohort information
can be found in Supplementary Table 1.
Replication
A cohort of individuals from the All New
Diabetics In Scania (ANDIS) and Scania
Diabetes Registry (SDR) studies was used
for further recapitulation and replication,
including type 1 diabetes case subjects
(N5 656), LADA case subjects (n5 823),
and population-based control subjects (N5
3,218). Details on the participants can be




All samples, except theWTCCC data, were
genotypedusing the IlluminaOmniExpress
genotyping chip. WTCCC type 1 diabetes
and type 2 diabetes case subjects were
genotyped using Affymetrix 500K, and
WTCCC control subjects were genotyped
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on the Illumina 1.2M BeadChip. Quality
control was performed using PLINK (15).
Individuals with ambiguous sex, geno-
type missingness .5%, genome-wide
heterozygosity (3 SDs from the mean),
duplicates, and related individuals were
excluded (see Supplementary Table 1 for
details). Principal componentanalysiswas
performed using PLINK, and outliers were
removed to exclude individuals with non-
European ancestry. Single nucleotide
polymorphisms (SNPs) with missing rate
,5%,minor allele frequency (MAF),1%,
and Hardy-Weinberg equilibrium exact
test P value ,1 3 1025 were removed
before HLA imputation.
HLA Imputation
Starting from the genotyped SNPs, we
imputed chromosome 6 using the HLA
imputation software SNP2HLA along with
the Type 1 Diabetes Genetics Consortium
(T1DGC) reference panel (16). A marker
window size of 1,000 base pairs and a
posterior probability (gprob) threshold of
0.5 were used. The HLA alleles of LADA
case subjects (n 5 1,428) and WTCCC
type 1 diabetes case subjects (n5 1,985)
were imputedtobothtwo-digit resolution
and four-digit resolution for increased
coverage and resolution of HLA alleles.
In total, there were 5,698 SNPs, 424 HLA
alleles, and 1,276 HLA amino acids. In
this study, we focused on a subset of
SNPs and HLA alleles that had an MAF
.1% in all three control cohorts (159
HLA alleles and 5,506 SNPs remained).
Power Calculations
Power calculations were performed us-




of 0.0036, 1,428 case and 2,979 control
subjects, and a significance level of 8.833
1026, basedonaBonferronicorrection for
the 5,665 variants tested (Supplementary
Table 2).
Recapitulation of a Previously
Published Conditional Analysis for
Type 1 Diabetes
Logistic regression using SNPTEST (17)
was used to test all HLA alleles and SNPs
with MAF .1% in all three control co-
horts. Sex and the 12 broad geographical
regions, provided by the WTCCC, were
includedas covariates in the analysis. The
analyses were performed in the WTCCC
type 1 diabetes versus control data sets
using forward stepwise conditional logis-
tic regression until there were no signif-
icantsignals remainingaftercorrection for
multiple testing.
Conditional Analysis in Subjects With
LADA Versus Population-Based
Control Subjects
Conditional logistic regression was per-
formedusingSNPTEST in theLADAversus
population-basedcontrol subjects, includ-
ing sex and the first four principal com-
ponents as covariates.
Replication
To further validate MHC class I indepen-
dent effects in type 1 diabetes and lack of
MHC class I independent effects in LADA,
we implemented approximate conditional
and joint (COJO) analysis in GCTA (18) on
summary statistics from the Swedish rep-
lication cohort. Association analysis was
performedusingSNPTEST, and sexand the
first four principal components were used
ascovariates.Therewere656casesubjects
with type 1 diabetes vs. 3,218 population-




We performed sensitivity analysis to de-
terminewhether the lack of independent
type1diabetes–associated signals inMHC
class I genes in LADA case subjects could
be due to a lack of power. We randomly
sampled 1,428 type 1 diabetes case sub-
jects and 714 type 1 diabetes cases sub-
jects (subsets equating to the same size as
the LADA cohort and half the size of the
LADA cohort, respectively) and 2,219 con-
trol subjects to determine whether the
type 1 diabetes–associated signals could
be still be detected. Stepwise conditional
logistic regression using SNPTEST was
performed as described above. To test
the hypothesis that LADA is a mixture
of type 1 diabetes and type 2 diabe-
tes cases, we performed a conditional
analysis in 714 randomly sampled type 1
diabetes cases and 714 randomly sam-
pled type 2 diabetes cases (total n 5




PLINK was used to calculate pairwise
linkage disequilibrium (LD) between
variants to further validate that the
associated variants were truly indepen-
dent of each other. For confirmation
of the independent association of
HLA-B*39, the specific HLA-B*39 subtype
HLA-B*3906 was tested in the WTCCC
type 1 diabetes case subject (n 5 1,985)
versus control subject (n 5 2,219) data
set with DQB1*0402 and DQB1*0501 as
covariates.
Ethics Approval
This study was approved by local institu-
tional ethics review boards.
RESULTS
Confirming Independent Effects of
MHC Class I Signals in WTCCC Subjects
With Type 1 Diabetes Versus Control
Subjects
Beforeconditioning,weobservedrs3957146
as the strongest association signal in
analysis of subjects with type 1 diabetes
versusWTCCC control subjects (P5 8.943
102165) (Fig. 1A). rs3957146 is in strong
LD with a classical HLA subtype allele,
HLA-DQB1*0302 (r2 5 0.99). After con-
ditioning on the top signal, rs3957146,
and subsequent independent MHC class II
signals (HLA-DQB1*0201 and rs9268633),
we observed the reported independent
significant association of MHC class I
variants rs1610649 (HLA-G, P 5 6.89 3
10223) andHLA-B*39 (P56.89310223)
(Fig. 1B, Table 1, Supplementary Table 3,
and Supplementary Fig. 2). Conditioning
on these variants in addition to theMHC
class II variants also demonstrated sig-
nificant associationwith theHLA-A locus
(rs9259852, P 5 2.04 3 1028).
Conditional Analysis in Subjects With
LADA Versus Population-Based
Control Subjects
We then went on to perform stepwise
conditional analysis in 1,428 LADA case
and 2,979 control subjects. Similar to
observations in the type 1 diabetes ver-
sus WTCCC control data set, before con-
ditioning on any variants, the strongest
association signal in LADA case subjects
versuspopulation-based control subjects
was also rs3957146 (P 5 1.80 3 10268)
(Fig. 2A). Although we had 98% power
to detect HLA-B*39 with an allele fre-
quency of 2% and an odds ratio of 2.5
(Supplementary Table 2), when condi-
tioning on the most highly significant
MHC class II alleles (rs3957146, HLA-
DRB1*03, rs9269081, DRB1*0404, and
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DQB1*0602), there were no remaining
independent signals in the MHC class I
region reaching significance after correc-
tion for multiple comparisons (P ,
8.833 1026) (Fig. 2B). Furthermore, we
also noted independent effects in the
MHCclass III region(rs2143462,P58.243
1028) and the MHC class II region (HLA-
DPA1*02,P51.6231026, andHLA-DPB1
variant rs3130192, P5 5.323 1026), which
are known to be associated with type 1
diabetes (19). Here, HLA-DPB1 variant
is in strong LDwith rs2301225 (r25 0.85)
and is independently associated with
type 1 diabetes. MHC class I variants
were not observed to be indepen-
dently associated with LADA after cor-
rection for multiple comparisons (Table 1,
Supplementary Fig. 2, and Supplementary
Table 4).
Sensitivity Analysis in Reduced Sample
of Subjects With Type 1 Diabetes
Versus Control Subjects
To ensure that the lack of significant
associationswithMHCclass I genes in the
LADA cohort was not explained by re-
duced power, we conducted a sensitivity
analysis by systematically decreasing the
sample size of the type 1 diabetes versus
WTCCC control cohort to match the size
Figure 1—Conditional analysis in 1,985 type 1 diabetes case and 2,219WTCCC control subjects. A: Logistic regression analysis without conditioning on
MHC class II alleles. B: Logistic regression analysis conditioning on MHC class II alleles. C: Logistic regression analysis conditioning on MHC class II and
MHC class I signals.
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rs3957146 HLA-DQA2 32789508 T/C 0.385 0.113 1.44 0.05 0.251 0.101 1.14 0.06 1.22 3 1024
DQB1*0201 HLA-DQB1 32739039 P/A 0.338 0.140 1.56 0.06 0.209 0.119 1.05 0.07 3.17 3 1028
rs9268633 HLA-DRA 32514451 G/A 0.983 0.803 1.46 0.10 0.919 0.812 0.83 0.06 6.58 3 1028
rs1610649 HLA-G 29876896 G/A 0.616 0.582 0.61 0.06 0.592 0.586 0.16 0.05 8.33 3 1029
B*39 HLA-B 31431272 P/A 0.043 0.016 1.36 0.17 0.023 0.019 0.58 0.19 2.22 3 1023
DRB1*0404 HLA-DRB1 32660042 P/A 0.082 0.048 1.04 0.13 0.037 0.035 1.01 0.14 0.88
rs17427599 HLA-DQB1 32775342 T/C 0.849 0.755 0.59 0.09 0.818 0.775 0.31 0.07 1.41 3 1022
rs2301225 HLA-DPA1 33143838 T/C 0.941 0.891 0.72 0.11 0.924 0.886 0.42 0.08 2.74 3 1022
rs397081 NOTCH4 32300595 T/C 0.095 0.045 0.79 0.12 0.075 0.054 0.64 0.10 0.34
rs9262545 MUC22 31101041 A/G 0.913 0.881 0.67 0.11 0.862 0.858 0.09 0.07 8.65 3 1026
rs9262547 MUC22 31101206 T/A 0.135 0.119 1.59 0.19 0.137 0.142 20.09 0.07 1.07310216
rs9259852 HLA-A 30004400 C/T 0.977 0.959 1.00 0.18 0.968 0.963 0.19 0.13 2.64 3 1024
rs9269081 HLA-DRA 32549078 A/C 0.890 0.735 0.57 0.11 0.821 0.685 0.71 0.05 0.25
rs1978029 HLA-DQB2 32839688 C/T 0.651 0.537 0.36 0.08 0.565 0.475 0.39 0.05 0.75
b-Coefficients and SEs are calculated for the risk allele frequency (RAF) from stepwise regression conditional on all SNP/HLA alleles (first column) in
1,985 type 1 diabetes case vs. 2,219 control subjects. b-Coefficients and SEs for LADA case vs. control subjects correspond with maximum effect
size in conditional analysis. P values are derived from two-sample Z test to formally test whether b-coefficients are significantly different. Forest plot is
shown in Supplementary Fig. 2. Three independent signals appeared in both type 1 diabetes and LADA conditional analyses (rs3957146, HLA-
DRB1*0404, and rs9269081); however, of these three signals, only rs3957146 had a significant difference in effect size between type 1 diabetes and
LADA (interaction P value 5 4.15 3 10210).
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of the discovery LADA cohort (n5 1,428
type 1 diabetes case and 2,219 control
subjects) andperforming conditional anal-
ysis. Independent significant associa-
tion signals at HLA-G (P 5 1.37 3 10217),
HLA-B (P 5 5.58 3 10214), and MUC22
(rs9262545, P 5 3.36 3 1029; rs9262547,
P5 9.693 10214) were still observed in
this reduced type 1 diabetes sample
size (Supplementary Table 5), although
these signals were missing in the com-
paratively sized LADA versus control
subjects data set. Similarly, indepen-
dent significant association signals at
HLA-B (P 5 1.26 3 10210), HLA-G (P 5
0.002), and MUC22 (rs9262545, P 5
1.57 3 1025) remained after further
reduction of the type 1 diabetes cohort
size to equate with half the LADA cohort
size (Supplementary Table 6).
Sensitivity Analysis in a Randomly
Mixed Cohort of Type 1 Diabetes and
Type 2 Diabetes Case Subjects Versus
Control Subjects
Another explanation for the lack of in-
dependent, significant associations across
MHC class I genes in LADA could be that
the LADA cohort simply represents
an ;50/50 mixture of misdiagnosed
type 1 diabetes and type 2 diabetes
cases. Therefore, we randomly sampled
714 type 1 diabetes case subjects, 714
type 2 diabetes case subjects, and 2,219
control subjects, creating a “mixture”
cohort. We performed the same condi-
tional analysis described above and
observed that the HLA-B, HLA-G, and
two MUCC2 signals in the MHC class
I regions remained independently sig-
nificant in this mixed cohort, driven
by the type 1 diabetes case subset
(Supplementary Table 7).
Replication
We leveraged summary statistics data
from Swedish cohorts to attempt repli-
cation of our findings. In type 1 diabetes
case versus control subjects, the stron-
gest association was rs9275206 (P 5
6.353 10289), which is in strong LDwith
HLA-DQB1*0302 (r2 5 0.99). After con-
ditioning on rs9275206 and subsequent
top signals (Supplementary Table 8), we
again observed significant association
signals at the HLA-G (P5 1.743 10210)
and HLA-B (1.103 1029) loci. However,
when conditional analysis was performed
inLADAcaseversuscontrolsubjects, there
were no such signals across MHC class I
genes and very sparse signals in the MHC
class II region (Supplementary Table 9).
Furthermore, we observed a significant
associationsignalat theNOTCH4 (rs397081,
P 5 1.11 3 10210) locus, the MUC22
locus (rs9262545,P57.833 10211, and
rs9262547, P 5 7.17 3 10217), and the
HLA-A locus (rs9259852, P 5 5.84 3
10214) (Fig. 1C). Notably, rs9259852 is in
strong LD with the classic HLA subtype
allele, HLA-A*32 (r2 5 0.96).
Further Validating HLA*B*39
It has been shown that the HLA-B*3906
allele is associated with a high risk of
diabetes only for specific HLA-DR/DQ
haplotypes, DRB1*0801-DQB1*0402 and
DRB1*0101-DQB1*0501 (20). With spe-
cific conditioning on these HLA-DR/DQ
haplotypes in theWTCCC type 1 diabetes
caseandcontrol cohort, the independent
significant association of the more spe-
cific HLA-B*3906 subtype still remained
(odds ratio 4.57 [95% CI 3.08–6.80]; P5
5.84 3 10214).
CONCLUSIONS
The main objective of this study was to
perform conditional analysis of the HLA
region in LADA, which has been under-
explored to date in this disease context.
The fewgenetic studies in LADA (5,21,22)
only focused on theHLA class IIDRB1 and
DQB1 haplotypes. Such studies, in pop-
ulations of both European and Chinese
ancestry, show that type 1 diabetes risk
haplotypes are less frequent in LADA
compared with childhood-onset type 1
diabetes case subjects, whereas type 1
Figure 2—Conditional analysis in 1,428 LADA case and 2,979 WTCCC control subjects. A: Logistic regression analysis without conditioning on MHC
class II alleles. B: Logistic regression analysis conditioning on MHC class II alleles.
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diabetes protective haplotypes are more
frequent in LADA, suggesting that LADA
is a genetically attenuated form of type 1
diabetes. By extending the analysis of
HLA in LADA beyond the MHC class II
region, we were able to observe further
genetic differences between LADA and
childhood-onset type 1 diabetes.
Although previous studies have re-
ported MHC class I independent effects
in type 1 diabetes, those studies directly
used HLA-typed case and control sub-
jects. Given the cost and challenges of
direct HLA typing, we utilized the impu-
tation tool SNP2HLA on genotyping data.
SNP2HLAhas been commonly used in the
field to assess the genetics of autoim-
mune diseases (16,23–25). Furthermore,
given that this approach differs from that
of Nejentsev et al. (11), it was crucial to
first ensure that we could recapitulate
the previously reported type 1 diabetes
observations in the same cohort. First,
we leveraged theWTCCC type 1 diabetes
case and control data set, as a positive
control, with previous studies identifying
MHC class I independent type 1 diabetes
associations in the MHC class I region
(8,10,11,26). Since these studies were
reported, imputation tools have allowed
the analysis of the HLA region more
cheaply and, in general, more practically.
Before investigating MHC class II inde-
pendent LADA associations in the MHC
class I region, given the difference in our
analytical approach, we recapitulated
the observations in previous studies
(10,11) by leveraging the same WTCCC
type 1 diabetes and control data sets.We
confirmed that MHC class I variants are
significantly associated with type 1 di-
abetes, independent of the MHC class II
region using this imputation-based ap-
proach followed by stepwise conditional
logistic regression. The conditional anal-
ysis was repeated in the LADA cohort,
which consisted of case and population-
based control subjects. Crucially, there
were no significant independent effects
in the MHC class I region remaining after
correction for multiple comparisons; fur-
thermore, this observation was replicated
in a separate Swedish cohort of type 1
diabetes case, LADA case, andpopulation-
based control subjects.
The MHC class I variant HLA-B*39 is
an established locus associated with
type 1 diabetes risk (10,11,27). More
specifically, studies suggested a strong
association with type 1 diabetes for the
subtype HLA-B*3906, which is now used
in type 1 diabetes genetic risk scores to
predict type 1 diabetes diagnosis (23). It
has also been shown that the B*3906
allele significantly enhances the risk of
type 1 diabetes when present on specific
HLA-DR/DQ haplotypes (e.g., DRB1 0801-
DQB1 0402 and DRB1 0101-DQB1 0501).
The frequency of HLA-B*3906 is differ-
ent among different populations and
heredidnot surviveourfilter of having an
MAF.1%in thereplicationcontrolcohort
of Swedes. Thus, it was excluded in the
analyses across the three cohorts. How-
ever, we confirmed that the HLA-B *3906
alleleremainedsignificantlyassociatedwith
type 1 diabetes after conditioning on the
presence of the DRB1 0801-DQB1 0402
and DRB1 0101-DQB1 0501 haplotypes.
Additionally,HLA-B*3906 is associatedwith
younger age-at-diagnosis in type 1
diabetes (9,11). A recent study using
a NOD mouse model showed that HLA-
B*3906 mediates the development of
CD81 T cells required for type 1 di-
abetes onset; moreover, in the context
of reduced immunological tolerance to
insulin, HLA-B*3906-transgenic NOD mice
develop type 1 diabetes at an accelerated
rate (28). The lack of an independent HLA-
B*39 association observed in the adult-
onset phenotype of LADA further confirms
the link between HLA-B*39 with autoim-
mune progression with earlier onset of
clinical disease.
HLA-B associations have been con-
firmed in a previous study (26), as well as
associations around HLA-G, which is ex-
pressed in human pancreas (29) andmay
play a role in autoimmune progression
(30). However, the MHC class I variant
rs1619379, located in HLA-G and ;100
kb telomeric of HLA-A, may be less in-
formative compared with HLA-A variants
in predicting type 1 diabetes risk (10).
This particular MHC class I variant was
independently significant in the down-
sampled type 1 diabetes cohort, but is in
strongLDwithHLA-Gvariants, rs1610649
and rs2735028, which were significantly
associated in the full type 1 diabetes
set, the mixture cohort consisting of
type 1 diabetes and type 2 diabetes
case subjects, and the type 1 diabetes
Swedish replication cohort. Addition-
ally, the MHC class I variants located
in the MUC22 locus have not been
replicated in separate cohorts and
likely form haplotypes with HLA class I
alleles.
One limitation of this study was that
we only tested variantswith anMAF.1%
inall threecontrol cohorts,which resulted
in filtering out many informative alleles
suchasHLA-B*3906. Byfilteringto include
only common alleles, we limited potential
discrepancies between populations and
were able to replicate our observations
across cohorts with different frequencies
of known risk variants. Furthermore, our
study is limited in power to assess the
underlying continuous traits of age at
onset, time to insulin, and autoantibody
titer; future well-designed, large studies
are needed to enable those analyses.
With larger and more complete data in
individuals, we can then formally test the
many competing hypotheses regarding
the state of LADA in the field. The hy-
pothesis that LADA exists as a disease
different from type 1 diabetes with both
overlapping genes and distinct genes is
unlikely, as we did not clearly observe
distinct susceptible loci that were unique
to LADA in this study or our previous
GWAS (5). Future studies leveraging case
subjects diagnosed with type 1 diabetes
andLADAacross theageofonset rangewill
be crucial to test the remaining hypoth-
eses, which are: 1) LADA is type 1 diabetes
with misdiagnosed type 2 case subjects
who are false positive for autoantibodies,
2) LADA cases are essentially type 1 di-
abetes at later onset with lower rates of
progression, 3) LADA is a form of diabetes
where case subjects have both type 1 and
type 2 risk alleles present at the individual
level. This first hypothesis (LADA is type 1
diabetes with misdiagnosed type 2 case
subjects who are false positive for auto-
antibodies) motivated the sensitivity anal-
ysis, in which we randomly sampled case
subjects from the WTCCC type 1 diabetes
and type 2 diabetes cohort to create a
random LADA cohort under the assump-
tion that the LADA group would be a
“mixture” of actual type 1 diabetes and
type 2 diabetes case subjects. In this
analysis, we still observed the same in-
dependent effects of MHC class I variants,
showing that the type1diabetes signature
remained in the “mixture” cohort despite
not being observed in LADA. However, we
recognize that type 1 diabetes case sub-
jects were sampled from the cohort of
childhood-onset type 1 diabetes and that
properly testing this hypothesis would
require that LADA cases be ascertained
from another cohort but also further
stratified by autoantibody titer.
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Although the underlying populations
fromwhich the type 1 diabetes and LADA
sets were derived are the same, we
addressed whether the LD structure in
the HLA region could be different be-
tween the two sample sets, which in turn
could have resulted in inaccurate impu-
tation. However, when we calculated LD
for theMHC region in these data sets, we
found it to be highly correlated (Pearson
correlation coefficient 5 0.97). Future
studies are needed to address this ques-
tion in-depth as well as validate these
findings in a cohort directly typed for
MHC class II and MHC class I HLA alleles.
Additionally, for further delineation of
this putative distinguishing genetic fea-
ture between LADA and childhood-onset
type 1 diabetes, it will be crucial to
investigate how the HLA profile com-
pares across the diabetes age continuum
stratified for different autoantibody pos-
itivity status. A previous study observed
different independent effects of MHC
class I variants to GAD autoantibodies
and insulinoma-associated antigen-2
autoantibodies (31).Additionally, studies
have shown that children with type 1
diabetes who are positive for a single
autoantibody are more like to show type
2 diabetes features (32,33), for instance,
a significant association with type 2 di-
abetes GWAS-implicated variants. Over-
all, our results point to key differences in
the genetic signature in the MHC region,
especially class I markers, between LADA
and childhood-onset type 1 diabetes.
This study highlights the clinical utility of
genetic screening in adult-onset diabetes
that may be autoimmune in origin. The
potential of defining these subjects who
are at risk for rapid loss of insulin secre-
tion using genetic characteristics could
enable targeted immune-based, disease-
modifying therapy.
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Baden-Württemberg, and a Ministry of Educa-
tion, Singapore, startup grant. S.F.A.G. is sup-
ported by the National Institutes of Health
(R01-DK-085212) and the Children’s Hospital
of Philadelphia Daniel B. Burke Endowed
Chair for Diabetes Research.
Duality of Interest. R.M. is currently affiliated
with GlaxoSmithKline. V.C.G. is currently affili-
atedwith Science 37. N.C.S. is currently affiliated
with Lilly Germany. No other potential conflicts
of interest relevant to this article were reported.
Author Contributions. R.M., M.Å., D.L.C., E.A.,
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N.C.S., B.F.V., B.O.B., R.D.L., and S.F.A.G. con-
tributed to drafting and critical revision of the
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